PROBUPHINE Drug Patent Profile

Which patents cover Probuphine, and what generic alternatives are available?

Probuphine is a drug marketed by Reacx Pharms and is included in one NDA.

The generic ingredient in PROBUPHINE is buprenorphine hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Probuphine

A generic version of PROBUPHINE was approved as buprenorphine hydrochloride by HOSPIRA on June 3^rd, 1996.

Summary for PROBUPHINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROBUPHINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Reacx Pharms	PROBUPHINE	buprenorphine hydrochloride	IMPLANT;IMPLANTATION	204442-001	May 26, 2016		DISCN	Yes	No

International Patents for PROBUPHINE

See the table below for patents covering PROBUPHINE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003240493	IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE
Australia	2008212011	Implantable polymeric device for sustained release of buprenorphine
Canada	2487577	DISPOSITIF POLYMERE IMPLANTABLE PERMETTANT LA LIBERATION PROLONGEE DE BUPRENORPHINE (IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE)
Cyprus	1120510
Denmark	2561860
European Patent Office	1509182	DISPOSITIF POLYMERE IMPLANTABLE PERMETTANT LA LIBERATION PROLONGEE DE BUPRENORPHINE (IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE)

Investment Scenario and Fundamentals Analysis for PROBUPHINE

Last updated: March 22, 2026

What is PROBUPHINE?

PROBUPHINE (probuphine implant) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in 2016. It delivers buprenorphine, a partial opioid agonist, via six months-long subdermal implant. It targets opioid dependence treatment, particularly for adults in maintenance therapy.

Market Overview and Potential

The opioid dependence treatment market faces increasing demand due to rising opioid misuse. PROBUPHINE is positioned as a long-acting alternative to daily buprenorphine prescriptions. The global opioid dependence treatment market size was valued at approximately US$3.1 billion in 2021, projected to grow at an annual rate of 5.2% through 2028 ([1]).

Key Markets

• United States accounts for over 85% of sales due to high opioid misuse rates.
• Europe and Asia-Pacific show emerging potential but regulatory pathways are complex.

Competitive Landscape

• Suboxone (buprenorphine/naloxone): The dominant oral/subcutaneous form.
• Sublocade (subcutaneous buprenorphine): Approved in 2017, offers monthly injections.
• Probuphine: The first implant approved for six months, has limited market penetration.

Sales and Revenue

Since FDA approval, PROBUPHINE has seen modest uptake. In 2020, reported U.S. sales were approximately US$25 million. The rollout faced delays due to insurance coverage issues and provider restrictions.

Analysts project sales could grow to US$150 million by 2025, driven by increased adoption in addiction clinics and physicians’ familiarity ([2]).

Regulatory and Reimbursement Environment

• FDA approval (2016): Validates safety and efficacy but emphasizes restricted use.
• Payer coverage: Limited early, now expanding as evidence of efficacy accrues.
• Reimbursement challenges: The implant procedure costs around US$800, with some payers being conservative.

R&D and Pipeline

No significant pipeline updates for PROBUPHINE itself. The focus remains on expanding technical training and clinician adoption.

Risks and Challenges

• Market penetration: Limited number of trained physicians and clinics.
• Regulatory hurdles: Restrictions on implant procedures.
• Insurance coverage: Still inconsistent, affecting adoption.
• Competition: Emergence of monthly injectable formulations with similar or better compliance profiles.

Investment Considerations

• Growth potential: Moderate, dependent on increased clinician training, payer acceptance, and patient preference shifts.
• Intellectual property: Patents expire around 2030, risking generic competition.
• Manufacturing: No reported issues; supply chain resilience appears stable.
• Market drivers: Rising opioid addiction rates, preference for long-acting formulations.

Financial Outlook

Expect incremental sales growth over the next five years, with upside in the event of expanded clinical adoption or regulatory changes favoring long-acting formulations. The current valuation reflects early-stage adoption risk.

Key Takeaways

• PROBUPHINE targets a growing opioid dependence market with limited direct competition but faces adoption hurdles.
• Commercial success hinges on expanding clinical acceptance, payer coverage, and overcoming procedural restrictions.
• Market size and sales projections position PROBUPHINE as a niche but potentially expanding product line in addiction therapy.
• Competitive pressure from monthly injectable options could erode market share if these demonstrate comparable efficacy and easier administration.
• Long-term valuation depends on sustained regulatory support and aggressive market clearing strategies.

FAQs

1. How does PROBUPHINE differ from other buprenorphine treatments?
PROBUPHINE is delivered via a long-acting implant that lasts six months, offering adherence benefits over daily or monthly injections. It requires a minor surgical procedure for placement and removal.

2. What are the main barriers to market expansion?
Limited provider training, procedural restrictions, insurance coverage variability, and competition from injectable formulations.

3. What is the compliance profile for PROBUPHINE?
High compliance due to the six-month duration reduces the risk of patient non-adherence common with daily pills.

4. How prone is the product to generic competition?
Patent protection lasts until around 2030; however, the implant device’s manufacturing process and formulations could face challenges from biosimilars or alternative delivery systems.

5. What regulatory trends could influence PROBUPHINE’s future?
Support for injectable long-acting formulations and policies reducing procedural barriers could enhance uptake. Conversely, adverse regulatory actions or restrictions on implant procedures could limit growth.

---

References

[1] MarketData Forecast. (2022). Global opioid dependence treatment market size and forecast.

[2] EvaluatePharma. (2021). Pharmaceutical sales and forecast data for long-acting buprenorphine products.